X.T.L. Biopharmaceuticals Ltd. - ADR
XTLB
Get informed when a big investor buys or sells
+ FollowMarket Cap$6.67M
Close$
$-1.75
160.9% downside
Current Fair Value
160.9% downsideOvervalued by 160.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $6.67 Million |
|---|---|
| Enterprise Value | $6.86 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-68 |
| Beta | 0.55 |
| Outstanding Shares | 105,163 |
Return
| Return on Equity | 404.33% |
|---|---|
| Return on Assets | -618.67% |
| Return on Invested Capital | 792.91% |
Valuation & Multiples
| P/E Ratio | -0.82 |
|---|---|
| PEG | 8.02 |
| Price to Sales | 0.72 |
| Price to Book Ratio | -0.96 |
| Enterprise Value to Revenue | 15.22 |
| Enterprise Value to EBIT | -3.41 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | -1.06 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
April 29, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 69.13%▼ 9.25% |
|---|---|
| Total Invested | $175,378▼ 8.12% |
| Investors Holding | 60% |
ESG Score
No data
About X.T.L. Biopharmaceuticals Ltd.
2,020 employees
CEO: Joshua Levine